Dr Najoua Lalaoui, a scientist at the Walter & Eliza Hall Institute of Medical Research in Australia, has been studying a new drug called birinapant that her research is showing could become one of the first targeted treatments for triple-negative breast cancer.
Triple-negative breast cancer is a particularly aggressive type of breast cancer for which no targeted treatments currently exist.
For many patients, chemotherapy may be the only option available. And while chemotherapy can be successful at treating and even curing cancer, it comes with toxic side effects and not all patients respond to chemotherapy in the same way.
We asked Dr Najoua Lalaoui to join us on a video call to tell us more about birinapant, her research, and what she hopes this exciting discovery could mean for the future of cancer research, and for patients with triple negative breast cancer.
Incredible discoveries like this would not happen without research – and research cannot happen without the support of people like you. If you’re feeling inspired, why not help us make the breakthroughs of the future by donating and starting new cancer cures today?
Donate now & become a Curestarter
Be part of a united effort to stop lives being cut short by cancer.
